APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mantle Cell Lymphoma Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchMantle Cell Lymphoma Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Mantle Cell Lymphoma Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Mantle Cell Lymphoma Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mantle Cell Lymphoma Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Mantle Cell Lymphoma Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Mantle Cell Lymphoma Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Mantle Cell Lymphoma Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Mantle Cell Lymphoma Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Mantle Cell Lymphoma Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Mantle Cell Lymphoma Therapeutics include Takeda Pharmaceutical Co. Ltd., Johnson & Johnson Services Inc., AstraZeneca Plc, Celgene Corp. and Allergan Plc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Mantle Cell Lymphoma Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Mantle Cell Lymphoma Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Mantle Cell Lymphoma Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Mantle Cell Lymphoma Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Mantle Cell Lymphoma Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Mantle Cell Lymphoma Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Mantle Cell Lymphoma Therapeutics Segment by Company

Takeda Pharmaceutical Co. Ltd.

Johnson & Johnson Services Inc.

AstraZeneca Plc

Celgene Corp.

Allergan Plc

Mantle Cell Lymphoma Therapeutics Segment by Type

Combination Therapy

Monotherapy

Mantle Cell Lymphoma Therapeutics Segment by Application

Hospital

Research Institute

Other

Mantle Cell Lymphoma Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mantle Cell Lymphoma Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mantle Cell Lymphoma Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mantle Cell Lymphoma Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Mantle Cell Lymphoma Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Mantle Cell Lymphoma Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mantle Cell Lymphoma Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Mantle Cell Lymphoma Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Combination Therapy Major Player Table 3. Monotherapy Major Player Table 4. Global Mantle Cell Lymphoma Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Research Institute Major Player Table 7. Other Major Player Table 8. Mantle Cell Lymphoma Therapeutics Industry Trends Table 9. Mantle Cell Lymphoma Therapeutics Industry Drivers Table 10. Mantle Cell Lymphoma Therapeutics Industry Opportunities and Challenges Table 11. Mantle Cell Lymphoma Therapeutics Industry Restraints Table 12. Global Mantle Cell Lymphoma Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Mantle Cell Lymphoma Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Mantle Cell Lymphoma Therapeutics Market Share by Region (2021-2026) Table 15. Global Mantle Cell Lymphoma Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Mantle Cell Lymphoma Therapeutics Market Share by Region (2027-2032) Table 17. Global Mantle Cell Lymphoma Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Mantle Cell Lymphoma Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Mantle Cell Lymphoma Therapeutics Key Players Headquarters & Area Served Table 21. Global Mantle Cell Lymphoma Therapeutics Players, Product Type & Application Table 22. Global Mantle Cell Lymphoma Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Mantle Cell Lymphoma Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Mantle Cell Lymphoma Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Mantle Cell Lymphoma Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Takeda Pharmaceutical Co. Ltd. Company Information Table 36. Takeda Pharmaceutical Co. Ltd. Business Overview Table 37. Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 39. Takeda Pharmaceutical Co. Ltd. Recent Development Table 40. Johnson & Johnson Services Inc. Company Information Table 41. Johnson & Johnson Services Inc. Business Overview Table 42. Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 44. Johnson & Johnson Services Inc. Recent Development Table 45. AstraZeneca Plc Company Information Table 46. AstraZeneca Plc Business Overview Table 47. AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Product Portfolio Table 49. AstraZeneca Plc Recent Development Table 50. Celgene Corp. Company Information Table 51. Celgene Corp. Business Overview Table 52. Celgene Corp. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Celgene Corp. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 54. Celgene Corp. Recent Development Table 55. Allergan Plc Company Information Table 56. Allergan Plc Business Overview Table 57. Allergan Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Allergan Plc Mantle Cell Lymphoma Therapeutics Product Portfolio Table 59. Allergan Plc Recent Development Table 60. North America Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 61. North America Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 62. North America Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 63. North America Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 64. North America Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 65. North America Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Mantle Cell Lymphoma Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 67. Europe Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 68. Europe Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 69. Europe Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 70. Europe Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 71. Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 73. Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 74. China Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 75. China Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 76. China Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 77. China Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 78. Asia Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 79. Asia Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 80. Asia Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 81. Asia Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 82. Asia Mantle Cell Lymphoma Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 83. Asia Mantle Cell Lymphoma Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 84. Asia Mantle Cell Lymphoma Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 85. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 86. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 87. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 88. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 89. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 91. SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Mantle Cell Lymphoma Therapeutics Image Figure 2. Global Mantle Cell Lymphoma Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mantle Cell Lymphoma Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Combination Therapy Image Figure 5. Monotherapy Image Figure 6. Global Mantle Cell Lymphoma Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Mantle Cell Lymphoma Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Research Institute Image Figure 10. Other Image Figure 11. Global Mantle Cell Lymphoma Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Mantle Cell Lymphoma Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Mantle Cell Lymphoma Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Mantle Cell Lymphoma Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Mantle Cell Lymphoma Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Mantle Cell Lymphoma Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Mantle Cell Lymphoma Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Mantle Cell Lymphoma Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Mantle Cell Lymphoma Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Mantle Cell Lymphoma Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Mantle Cell Lymphoma Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Therapy
  • Monotherapy
Applications
  • Hospital
  • Research Institute
  • Other
Companies covered
  • Takeda Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services Inc.
  • AstraZeneca Plc
  • Celgene Corp.
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Mantle Cell Lymphoma Therapeutics Market by Type
  3. 1.2.1 Global Mantle Cell Lymphoma Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Combination Therapy
  5. 1.2.3 Monotherapy
  6. 1.3 Mantle Cell Lymphoma Therapeutics Market by Application
  7. 1.3.1 Global Mantle Cell Lymphoma Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Research Institute
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Mantle Cell Lymphoma Therapeutics Market Dynamics
  1. 2.1 Mantle Cell Lymphoma Therapeutics Industry Trends
  2. 2.2 Mantle Cell Lymphoma Therapeutics Industry Drivers
  3. 2.3 Mantle Cell Lymphoma Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mantle Cell Lymphoma Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Mantle Cell Lymphoma Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Mantle Cell Lymphoma Therapeutics Growth Trends by Region
  3. 3.2.1 Global Mantle Cell Lymphoma Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Mantle Cell Lymphoma Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Mantle Cell Lymphoma Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Mantle Cell Lymphoma Therapeutics Revenue by Players
  2. 4.1.1 Global Mantle Cell Lymphoma Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Mantle Cell Lymphoma Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Mantle Cell Lymphoma Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Mantle Cell Lymphoma Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Mantle Cell Lymphoma Therapeutics Players, Product Type & Application
  8. 4.5 Global Mantle Cell Lymphoma Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Mantle Cell Lymphoma Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Mantle Cell Lymphoma Therapeutics Tier 1, Tier 2, and Tier 3
5 Mantle Cell Lymphoma Therapeutics Market Size by Type
  1. 5.1 Global Mantle Cell Lymphoma Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Type (2021-2032)
6 Mantle Cell Lymphoma Therapeutics Market Size by Application
  1. 6.1 Global Mantle Cell Lymphoma Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Mantle Cell Lymphoma Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Co. Ltd.
  2. 7.1.1 Takeda Pharmaceutical Co. Ltd. Company Information
  3. 7.1.2 Takeda Pharmaceutical Co. Ltd. Business Overview
  4. 7.1.3 Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
  7. 7.2 Johnson & Johnson Services Inc.
  8. 7.2.1 Johnson & Johnson Services Inc. Company Information
  9. 7.2.2 Johnson & Johnson Services Inc. Business Overview
  10. 7.2.3 Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Product Portfolio
  12. 7.2.5 Johnson & Johnson Services Inc. Recent Developments
  13. 7.3 AstraZeneca Plc
  14. 7.3.1 AstraZeneca Plc Company Information
  15. 7.3.2 AstraZeneca Plc Business Overview
  16. 7.3.3 AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Product Portfolio
  18. 7.3.5 AstraZeneca Plc Recent Developments
  19. 7.4 Celgene Corp.
  20. 7.4.1 Celgene Corp. Company Information
  21. 7.4.2 Celgene Corp. Business Overview
  22. 7.4.3 Celgene Corp. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Celgene Corp. Mantle Cell Lymphoma Therapeutics Product Portfolio
  24. 7.4.5 Celgene Corp. Recent Developments
  25. 7.5 Allergan Plc
  26. 7.5.1 Allergan Plc Company Information
  27. 7.5.2 Allergan Plc Business Overview
  28. 7.5.3 Allergan Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Allergan Plc Mantle Cell Lymphoma Therapeutics Product Portfolio
  30. 7.5.5 Allergan Plc Recent Developments
8 North America
  1. 8.1 North America Mantle Cell Lymphoma Therapeutics Revenue (2021-2032)
  2. 8.2 North America Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Mantle Cell Lymphoma Therapeutics Revenue by Country
  11. 8.6.1 North America Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Mantle Cell Lymphoma Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Mantle Cell Lymphoma Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Mantle Cell Lymphoma Therapeutics Revenue by Country
  11. 9.6.1 Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Mantle Cell Lymphoma Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Mantle Cell Lymphoma Therapeutics Revenue (2021-2032)
  2. 10.2 China Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Mantle Cell Lymphoma Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Mantle Cell Lymphoma Therapeutics Revenue by Country
  11. 11.6.1 Asia Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Mantle Cell Lymphoma Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Mantle Cell Lymphoma Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Mantle Cell Lymphoma Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Mantle Cell Lymphoma Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Mantle Cell Lymphoma Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst